Halyard Health (NYSE:HYH) was upgraded by equities research analysts at TheStreet from a “c+” rating to a “b” rating in a report released on Monday.

Several other equities research analysts have also weighed in on HYH. BidaskClub upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. Stifel Nicolaus restated a “buy” rating and set a $45.00 price objective on shares of Halyard Health in a report on Thursday, September 21st. Zacks Investment Research lowered shares of Halyard Health from a “buy” rating to a “sell” rating in a report on Wednesday, October 4th. KeyCorp restated a “hold” rating on shares of Halyard Health in a report on Tuesday, October 17th. Finally, ValuEngine upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $44.00.

Shares of Halyard Health (NYSE HYH) opened at $47.41 on Monday. The company has a quick ratio of 1.19, a current ratio of 2.13 and a debt-to-equity ratio of 0.49. The firm has a market cap of $2,253.77, a price-to-earnings ratio of 23.02, a price-to-earnings-growth ratio of 2.60 and a beta of 1.77. Halyard Health has a twelve month low of $35.24 and a twelve month high of $50.99.

Halyard Health (NYSE:HYH) last posted its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.13. The company had revenue of $401.40 million for the quarter, compared to analyst estimates of $394.54 million. Halyard Health had a net margin of 3.52% and a return on equity of 8.65%. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period last year, the business posted $0.48 earnings per share. sell-side analysts anticipate that Halyard Health will post 2.08 EPS for the current year.

Several large investors have recently modified their holdings of the stock. Amalgamated Bank raised its holdings in shares of Halyard Health by 1.2% during the second quarter. Amalgamated Bank now owns 6,655 shares of the medical instruments supplier’s stock worth $261,000 after acquiring an additional 82 shares during the period. Texas Permanent School Fund grew its position in Halyard Health by 0.8% in the second quarter. Texas Permanent School Fund now owns 34,074 shares of the medical instruments supplier’s stock valued at $1,338,000 after purchasing an additional 284 shares in the last quarter. Arizona State Retirement System grew its position in Halyard Health by 1.5% in the second quarter. Arizona State Retirement System now owns 19,700 shares of the medical instruments supplier’s stock valued at $774,000 after purchasing an additional 300 shares in the last quarter. State Treasurer State of Michigan grew its position in Halyard Health by 1.6% in the second quarter. State Treasurer State of Michigan now owns 19,220 shares of the medical instruments supplier’s stock valued at $755,000 after purchasing an additional 300 shares in the last quarter. Finally, Capstone Asset Management Co. grew its position in Halyard Health by 6.2% in the second quarter. Capstone Asset Management Co. now owns 5,663 shares of the medical instruments supplier’s stock valued at $222,000 after purchasing an additional 330 shares in the last quarter. Institutional investors and hedge funds own 90.31% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/06/halyard-health-hyh-upgraded-by-thestreet-to-b.html.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.